Equities

Glenmark Pharmaceuticals Ltd

GLENMARK:NSI

Glenmark Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,646.05
  • Today's Change-71.05 / -4.14%
  • Shares traded1.60m
  • 1 Year change+92.77%
  • Beta1.1516
Data delayed at least 15 minutes, as of Sep 18 2024 11:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform2
Hold3
Sell1
Strong Sell0

Share price forecast in INR

The 12 analysts offering 12 month price targets for Glenmark Pharmaceuticals Ltd have a median target of 1,575.00, with a high estimate of 1,900.00 and a low estimate of 570.00. The median estimate represents a -4.10% decrease from the last price of 1,642.40.
High15.7%1,900.00
Med-4.1%1,575.00
Low-65.3%570.00

Dividends in INR

In 2024, Glenmark Pharmaceuticals Ltd reported a dividend of 2.50 INR, equaling last years dividend. The 6 analysts covering the company expect dividends of 3.37 INR for the upcoming fiscal year, an increase of 34.72%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in INR

On May 24, 2024, losses of -27.65 per share.
Average growth rate-9.39%
Glenmark Pharmaceuticals Ltd reported annual 2024 losses of -35.37 per share on May 24, 2024.
Average growth rate+14.31%
More ▼

Revenue history & estimates in INR

Glenmark Pharmaceuticals Limited had 1st quarter 2025 revenues of 32.44bn. This missed the 32.92bn consensus estimate of the 4 analysts following the company. This was 2.76% below the prior year's 1st quarter results.
Average growth rate+0.60%
Glenmark Pharmaceuticals Limited had revenues for the full year 2024 of 118.13bn. This was 7.52% below the prior year's results.
Average growth rate+2.90%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.